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Vitiligo represents the most common cause of acquired skin, hair, and oral depigmen-
tation, affecting 0.5–1% of the population worldwide. It is clinically characterized by the 
appearance of disfiguring circumscribed skin macules following melanocyte destruction 
by autoreactive cytotoxic T  lymphocytes. Patients affected by vitiligo usually show a 
poorer quality of life and are more likely to suffer from depressive symptoms, particularly 
evident in dark-skinned individuals. Although vitiligo is a non-fatal disease, exposure of 
affected skin to UV light increases the chance of skin irritation and predisposes to skin 
cancer. In addition, vitiligo has been associated with other rare systemic disorders due 
to the presence of melanocytes in other body districts, such as in eyes, auditory, ner-
vous, and cardiac tissues, where melanocytes are thought to have roles different from 
that played in the skin. Several pathogenetic models have been proposed to explain 
vitiligo onset and progression, but clinical and experimental findings point mainly to 
the autoimmune hypothesis as the most qualified one. In this context, it is of relevance 
the strong association of vitiligo with other autoimmune diseases, in particular with 
autoimmune thyroid disorders, such as Hashimoto thyroiditis and Graves’ disease. In 
this review, after a brief overview of vitiligo and its pathogenesis, we will describe the 
clinical association between vitiligo and autoimmune thyroid disorders and discuss the 
possible underlying molecular mechanism(s).
Keywords: vitiligo, autoimmune thyroid diseases, tyrosinase, TSH receptor, thyroglobulin, reactive oxygen 
species, CD8+ T cells, autoimmune polyendocrine syndromes
viTiLiGO: An OveRview
Vitiligo represents the most common cause of acquired skin, hair and oral depigmentation, and often 
occurs as an inherited disease (1). Clinically, it is characterized by the progressive loss of melanocytes 
causing the appearance of well-circumscribed milky/white cutaneous macules. Histologically, skin 
lesions show basal hypopigmentation and increased dermal inflammation relative to perilesional 
normal skin, with complete or near-complete loss of melanocytes at the basal epidermal layer (2). 
Following the Vitiligo Global Issues Consensus Conference in 2011, the disease has been categorized 
based on clinical parameters into: segmental vitiligo (SV), non-segmental vitiligo (NSV), and mixed 
vitiligo (MV) (1). SV is characterized by a unilateral distribution of the macules and is less common 
compared with the NSV, which shows symmetrical and bilateral white patches (3). NSV includes 
different clinical vitiligo subtypes, namely, acrofacial, generalized, mucosal, and universal vitiligo. 
NSV may be initially classified as acrofacial and, over time, be reclassified as generalized or universal 
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vitiligo. On the other hand, MV includes the combination of an 
initial SV followed by the occurrence, after several months or 
years, of bilateral NSV patches (1, 4).
The prevalence of vitiligo has been estimated to be 0.5–1% 
of the world population. However, it can vary from country to 
country. In fact, the prevalence recorded in Denmark is 0.38%, 
whereas in India it is up to 8.8% (1, 5, 6). Vitiligo can arise at any 
age, even if about 50% of cases are diagnosed before the age of 20, 
and both sexes are equally affected (1, 6).
Due to its disfiguring effects, vitiligo may have a detrimental 
impact on patient’s quality of life (QoL) and mental health (7–9). 
A recent review of studies published over the last two decades 
indicates that women show more QoL impairment than men, 
married women more than singles, young patients more than 
elderly ones, and dark-skinned people more than white people 
(7, 8). Moreover, a recent meta-analysis demonstrated that vitiligo 
patients were significantly more likely to suffer from depression 
(9). Although vitiligo is a non-fatal disease, exposure of affected 
skin to UV light increases the chance of skin irritation and cancer 
(10). Furthermore, vitiligo has been associated with other rare 
systemic disorders, including the Vogt–Koyanagi–Harada, the 
Kabuki, and mitochondrial encephalopathy, lactic acidosis, and 
stroke-like episodes (MELAS) syndromes due to the presence of 
melanocytes in other parts of the body, such as in eyes, auditory, 
nervous, and cardiac tissues, where melanocytes are thought to 
have different roles from that played in the skin (11). In par-
ticular, the Vogt–Koyanagi–Harada disease is an autoimmune 
multisystemic disorder branded by granulomatous panuveitis 
with exudative retinal detachments, neurologic and hearing 
manifestations, and vitiligo. The Kabuki syndrome manifests 
with abnormalities in multiple organ systems and is character-
ized by distinctive facial features, including arched eyebrows, 
long eyelashes, long openings of the eyelids with the everted 
lower lids, and large protruding earlobes. It usually associates 
with autoimmune diseases such as idiopathic thrombocytopenic 
purpura, hemolytic anemia, thyroiditis, and vitiligo. The MELAS 
syndrome is a mitochondrial disorder due to mutations of the 
mitochondrial genome. The typical presentation of patients with 
MELAS syndrome is described by the name of the disorder. 
Additional features are seizures, diabetes mellitus, hearing loss, 
cardiac disease, short stature, endocrinopathies, neuropsychiat-
ric dysfunctions and skin alterations including hypertrichosis, 
eczema, and vitiligo.
PATHOGeneSiS
Although several hypotheses have been put forward to explain 
vitiligo ethiopathogenesis, the autoimmune theory is the most 
accredited one, being sustained by several epidemiological, 
clinical, and experimental findings (4, 9, 11–17). These studies 
indicate that melanocyte defects drive vitiligo pathogenesis by 
triggering, in susceptible individuals, an autoimmune response 
that leads to melanocyte destruction (11). Several exogenous and 
endogenous stimuli have been linked to the onset of the disease. 
The exogenous factors include ultraviolet irradiations, trauma 
(Koebner phenomenon), stress, major infections, malignan-
cies, neural abnormalities, vaccinations, pregnancy, calcium 
imbalance, certain drugs, hormones, and exposure to cytotoxic 
compounds. Among the endogenous factors are melanin synthe-
sis, cellular metabolism, proliferation, differentiation, apoptosis, 
and immune reactions (11, 14, 18–20). All of these are thought 
to induce oxidative stress in melanocytes, as indicated by the 
high levels of reactive oxygen species (ROS), mainly hydrogen 
peroxide and peroxinitrite, found in lesional skin (11, 14, 18–20). 
The ROS increase may also result from compromised antioxidant 
responses with local and/or systemic imbalance of the antioxidant 
systems (11, 14, 18–20). For example, the superoxide dismutase 
is present at higher levels in perilesional skin and patient’s sera 
(17, 20), whereas the level of the antioxidant enzyme catalase 
was found reduced in the vitiliginous skin compared with 
normal skin (20). The important role played by the antioxidant 
system in the pathogenesis of vitiligo is further corroborated 
by a recent study showing the association between a single 
nucleotide polymorphism of the nuclear factor, erythroid 2 like 2 
(NRF2) gene and vitiligo (19, 21). The transcription factor Nrf2 
regulates genes containing the antioxidant response elements 
(AREs) in their promoters and encoding proteins that protect 
against oxidative damage triggered by injury and inflammation. 
In addition, it has been shown that Nfr2-ARE/heme oxygenase-1 
pathway is functionally deficient in the disease-free epidermis of 
patients with vitiligo (22). This is in agreement with very recent 
findings showing the ability of simvastatin to protect human 
melanocytes from H2O2-induced oxidative stress by activating 
Nrf2 (23). Finally, reduced levels of non-enzymatic antioxidants 
such as beta-carotene, ubiquinone, vitamins E and C, ferritin, and 
metallothionein may contribute to the increased amount of ROS 
observed in vitiliginous melanocytes (19).
Oxidative stress may affect the structure and functions of the 
endoplasmic reticulum (ER), which act as a cellular stress sensor. 
Dilation of the ER is a hallmark of melanocytes at the periphery 
of vitiligo lesions, and the disruption of redox reactions, critical 
for proper protein folding, causes the accumulation of immature 
proteins and misfolded peptides leading to the activation of the 
unfolded protein response (UPR) (24, 25). The latter, under 
sustained cellular stress, promotes autoimmune responses via 
apoptotic cascades (19). Actually, exposure to chemical triggers 
of vitiligo was shown to induce oxidative stress and to promote 
UPR activation in melanocytes (26). The importance of the UPR 
in the pathogenesis of vitiligo is further corroborated by several 
lines of experimental evidence, which identified the X-box 
binding protein 1 (XBP1) gene, encoding a transcription factor 
mediating UPR activation, as a susceptibility locus for general-
ized vitiligo (27–30). The UPR induces also the expression of 
cytokines, such as IL-6, IL-8, IL-11, and tumor necrosis factor, 
and can attract cells of the innate immune system to the skin 
of vitiligo patients, as documented by the aberrant activation 
of natural killer and dendritic cells (DCs) in lesional skin (11). 
More recently, a role for calreticulin (CRT), an ER protein regu-
lating intracellular Ca2+, has been proposed in the progression 
of vitiligo (19). In particular, a redistribution of CRT from the 
ER lumen to the plasma membrane of melanocytes takes place 
under oxidative stress (19). Surface CRT is thought to direct the 
contact of stressed melanocytes with DCs, eliciting downstream 
immune responses and melanocyte apoptosis. The latter provides 
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abundant antigenic peptides to the antigen-presenting cells lead-
ing to the activation of T cells, thus promoting autoimmunity. 
In this context, it is also worth to consider that the increased 
ROS levels are thought to modify tyrosinase (TYR) and other 
melanogenic proteins into neoantigens (11). Indeed, patients 
affected by vitiligo show circulating autoantibodies directed 
toward specific melanocyte antigens such as TYR, tyrosinase-
related protein-1 (TRP-1), TRP-2, Pmel17 (or gp100), and type 1 
membrane receptor for melanin-concentrating hormone, whose 
serum level correlates with the disease severity (11, 31–36). In 
early lesions, CD8+ cytotoxic T  lymphocytes have been found 
close to melanocytes, and a perivascular lymphocytic infiltrate 
could be appreciated at the expanding edge of active skin lesions 
(37). In addition, the concentration of melanocyte-specific 
CD8+ T cells is higher in the blood of patients affected by vitiligo 
and correlates with disease activity (11, 31, 38). Furthermore, 
interferon-γ (IFN-γ) has been shown to play a central role in 
vitiligo progression through the release of several chemokines, 
such as CXCL9, 10, and 11 (17, 39). It has been also suggested 
that IFN-γ could play a direct role in vitiligo pathogenesis fol-
lowing the observation that the IFN-γ derived from cytotoxic 
T cells could itself cause apoptosis in melanocytes (40). This is 
in agreement with recent studies showing that human vitiligo 
as well as a mouse model of vitiligo reflects an IFN-γ-specific 
Th1 immune response in the skin that involves IFN-γ-dependent 
chemokines (41–44).
Recent findings indicate the participation in this process of 
TH17 cells, identified in the lesional skin of vitiligo patients 
(45, 46). The TH17 cells, by releasing interleukin-17, may induce 
in activated immune cells secretion of proinflammatory cytokines, 
which in turn recruit and activate mononuclear lymphocytes, 
strongly involved in disease progression (46). Finally, regula-
tory T cells (Treg), which are in charge to maintain peripheral 
tolerance through the suppression of self-reactive T cells, appear 
reduced in number and functionally flawed in lesional skin of 
patients affected by vitiligo (47).
A number of studies have shown that the uptake by keratino-
cytes of the melanocyte released melanosomes take place through 
phagocytic ingestion in a receptor-mediated process, involving 
the protease-activated receptor-2 and keratinocyte growth factor 
receptor/fibroblast growth factor receptor 2b (KGFR/FGFR2b) 
(48–50). A recent work reported a decreased expression of KGF/
FGF7 and its receptor in pathological hypopigmented skin, which 
may contribute to the formation of the classical milky macules of 
vitiligo (50).
Finally, it is worth to mention that a number of genome-wide 
association and genetic linkage studies identified more than 30 
different genes related to an increased risk of vitiligo, the majority 
of which are immune genes implicated in both the innate and the 
adaptive immune responses (4, 9, 11, 13).
ASSOCiATiOn wiTH AUTOiMMUne 
THYROiD DiSeASeS (AiTD)
Besides the abovementioned involvement of the immune sys-
tem in vitiligo pathogenesis, epidemiological evidence further 
corroborates the autoimmune genesis of vitiligo. In particular, 
vitiligo is present within the autoimmune polyendocrine syn-
dromes (51), and it is more frequently encountered in family 
members of patients affected by autoimmune diseases, such as 
inflammatory bowel disease, psoriasis, rheumatoid arthritis, 
type 1 diabetes, systemic lupus erythematosus, pernicious 
anemia, and AITD (31, 52–69). The latter, as outlined in several 
studies performed over the last decades, represent the most 
frequent autoimmune disorders associated with vitiligo (54, 
58, 66–73). A recent meta-analysis, performed on 48 articles 
published between 1968 and 2012, showed that in patients 
affected by vitiligo the prevalence of AITD was 14.3%, while 
positivity to thyroid-specific antibodies [i.e., anti-thyroglobulin 
(Tg), anti-thyroid peroxidase, and anti-thyrotropin recep-
tor (TSHR)] was found in 20.8% of them (74). Moreover, the 
presence of anti-thyroid hormones antibodies in the serum of 
patients affected by vitiligo was detected in 77 out of 79 viti-
ligo patients analyzed, suggesting a possible pathogenetic role 
(70, 75). Vice versa, the prevalence of vitiligo among AITD 
patients has been reported to vary from 2.7 to 7% (66, 67, 76, 77). 
It is also worth to note that the risk of thyroid disease in vitiligo 
patients increases with age (71, 74). All together, these findings 
have led to the recommendation of screening patients affected 
by vitiligo for thyroid diseases and thyroid autoantibodies, in 
an effort to detect undiagnosed thyroid diseases or to assess the 
risk of future onset (74, 78).
MOLeCULAR MeCHAniSMS 
UnDeRLYinG viTiLiGO AnD THYROiD 
AUTOiMMUne DiSeASe ASSOCiATiOn
The reported association of vitiligo with AITD suggests the 
presence of shared heritable susceptibility genes (79–87). 
Thirty-seven susceptibility genes have been identified for viti-
ligo disease and more than 15 for AITD (79–87). Genome-wide 
linkage analysis and candidate gene association studies identi-
fied nine loci potentially involved in both AITD and vitiligo 
(79–81). Among these, there are organ-specific genes such as 
those coding for TYR, Tg, and TSHR (81–85). In addition, an 
autoimmunity susceptibility locus (AIS1) was identified by 
genome-wide linkage analysis on chromosome 1 in families 
characterized by vitiligo and Hashimoto’s thyroiditis (HT) 
(86–88). Among the 27 genes mapping to the AIS1 locus, the 
forkhead transcription factor D3 appears to be the most plau-
sible responsible for the concomitant occurrence of vitiligo and 
AITD (86, 89). In addition, a single nucleotide polymorphism 
of the PTPN22 gene, encoding a lymphoid specific phosphatase, 
is shared among patients with vitiligo and AITD (79). These 
findings suggest that the association observed between vitiligo 
and AITD could be explained, at least in part, by the sharing of 
a subset of susceptibility genes.
Of interest are the recently reported observations showing 
melanocyte-specific antigen expression in thyroid tissues of patients 
with HT, as well as in thyroid tissues of healthy individuals (88). 
In particular, thyroid tissues from HT patients without vitiligo, 
and normal thyroid tissues, were both negative for the expression 
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of NKI/beteb, Pmel17, TRP-1, HMB-45, and S100, whereas they 
were positive for the expression of TRP-2, lysosome-associated 
membrane protein 1 (LAMP1), and CD69. Interestingly, TYR 
was only detected in thyroid from HT patients. Moreover, levels 
of LAMP1 and CD69 were higher in thyroid with HT compared 
with normal thyroid (90). The differences in type and amount of 
melanocyte antigens observed in the thyroid of HT patients may 
provide the immunological basis for secondary vitiligo associated 
with HT. Vice versa, different skin cell types, including keratino-
cytes, dermal fibroblasts, and melanocytes, have been shown to 
express functional TSHR and other thyroid-specific antigens 
including Tg, thyroperoxidase, and natrium/iodide symporter 
(91, 92). Thus, it may be speculated that in vitiligo patients the 
activation of the immune system against these antigens expressed 
in vitiliginous melanocytes may cause a secondary AITD.
COnCLUSiOn
Knowledge regarding the pathogenesis of vitiligo has consid-
erably increased over the last decades starting to clarify the 
molecular mechanisms underlying disease etiology and progres-
sion, as well as the association with other autoimmune disorders. 
Several susceptibility genes have been identified in both vitiligo 
and AITD patients that, along with the identification of shared 
antigens between melanocytes and thyrocytes, may contribute 
to explain the observed association between AITD and vitiligo.
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